



2018

DECEMBER 4-8

HENRY B. GONZALEZ CONVENTION CENTER,
SAN ANTONIO, TEXAS, USA



WELCOME

Welcome to the 2018 San Antonio Breast Cancer Symposium® (SABCS®), a joint presentation of the UT Health Cancer Center, Baylor College of Medicine, and the American Association for Cancer Research (AACR).

At SABCS 2018 you will be presented with a wide variety of new findings dealing with both optimizing clinical breast cancer management today and pointing the way to promising new treatment possibilities for the near future. There will be studies of new drugs and mechanisms as well as the best use and most effective combinations of existing drugs. Molecular findings leading to new targeted therapies will be discussed. There will be new advances in the widening field of immunotherapy, and studies of biomarkers ranging from circulating cells and their DNA to imaging and treatment response prediction. Local-regional treatments including surgical approaches and the possibility of axillary de-escalation will be presented, and one general session this year will be devoted largely to radiation therapy. And survivorship issues including quality of life concerns, lifestyle interventions, and costs will receive attention as well.

There is so much important work going on in the breast cancer field that it is a challenge to address it all during the symposium's 5 days. We begin with 2 workshops at 11:45 am on Tuesday, followed by 12 educational sessions (an increase from 9 in previous years). The rest of the program follows Wednesday through Saturday with multiple plenary & award lectures, mini-symposia, panel discussions, case discussions and poster sessions, not to mention an Oxford-style debate, a new item introduced last year to very positive response.

Aside from the main program, the Career Development Forum has returned, supplemented by a new Young Career Lounge, which offers a place to network as well as informal programs & discussions.

A new addition to the program, "Networking with the Experts" is a "can't miss" opportunity for young and established investigators alike. The event, which takes place in exhibit area at Noon on Friday, will have three groups focusing on several rapidly advancing areas of research hosted by luminaries in the respective fields; there will be no formal program. It's a fun opportunity to socialize and network with colleagues and potential collaborators working in your area, as well as some of the most respected investigators in the breast cancer research community. See the (newly redesigned!) pocket program or the SABCS app for details.

Questions and discussion are an important part of our sessions, but not everyone can get to the microphone, so a "Q&A" function has been added to the app through which questions can be sent to the moderator.

We think that all breast cancer professionals will find the program informative regarding the expanding frontiers of our knowledge, showing the way to future progress. Our goal is not only to share information, but also to stimulate new and productive collaborations.

And don't forget to take in the exhibit area, where our many exhibitors present new products and technologies that could enhance both our research and our patient care. When you need a break, step out and enjoy the holiday lights on the Riverwalk, lined with superb restaurants and lively music, only in San Antonio!

ISSUE 1 AT A GLANCE

- 1 Welcome
- 2 Plenary Lecture Schedule
MOC CME Information
Program Update - General Session 1
- 3 Scholarship Recipients
- 4 Product Theatre Schedule
Awards
- 5 Awards
- 6 Special Appreciation
Grants
Supporters
- 7 Exhibitors



WiFi Access

HOW TO CONNECT:

- 1: In your wireless settings scan for available wireless networks.
- 2: Connect to **SABCS2018**
- 3: Open your favorite browser.
- 4: When symposium welcome page loads you are connected!



PLENARY LECTURE SCHEDULE

HALL 3

PLENARY LECTURE 1

Wednesday, Dec 5 • 8:15 AM

Breast Tumor Evolution and Intratumor Heterogeneity - Insights from Single Cell Genomics

Nicholas E. Navin, PhD
UT MD Anderson Cancer Center
Houston, TX

PLENARY LECTURE 2

Thursday, Dec 6 • 9:00 AM

Neoadjuvant Endocrine Therapy: The Times They are A-Changing

Ingrid A. Mayer, MD, MSCI
Vanderbilt University Medical Center
Nashville, TN

SATELLITE SYMPOSIA

MARRIOTT RIVERCENTER

Wednesday, Dec 5

7:30 PM - 9:30 PM

Advances in HR+/HER2- Metastatic Breast Cancer: Current Practice, Open Questions, and Future Directions

Hosted by Clinical Care Options

Triple-Negative Breast Cancer - Developing a More Positive Approach

Hosted by Prime Oncology

*AT PRESS TIME

MOC CME

Maintenance of Certification Part II

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 40.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Participating in MOC II:

Approximately two months after the conclusion of the 2018 symposium, a highlight report from the symposium will be posted on SABCS.org. Physicians certified by the American Board of Internal Medicine (ABIM) interested in requesting ABIM MOC will be asked to complete a reflections and feedback form based on your understanding of the report. Evidence has shown that careful reflection during and after an educational activity leads to increased knowledge retention and greater chance of transforming information into action. Information on participating in MOC II will be available at SABCS.org.

PROGRAM UPDATE:

DISCUSSANT ADDED - GENERAL SESSION 1

A discussant has been added to General Session 1 following the 11:00 am presentation of GS1-10 "Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE."

Dr. Eric Winer, Dana-Farber Cancer Institute, will discuss the subject beginning at 11:15 am.

The William L. McGuire Memoria lecture will follow at 11:30 am.

WITHDRAWN ABSTRACTS

- | | |
|----------|----------|
| P1-02-08 | P1-11-05 |
| P1-06-09 | P1-12-02 |
| P1-08-34 | P1-19-04 |
| P1-09-03 | |

SABCS 2018 SCHOLARSHIP RECIPIENTS

Three programs provided scholarships designed to promote the education and professional development of early-career scientists who are actively pursuing research in breast cancer by facilitating their attendance at SABCS. Scholarships were awarded to graduate students, medical students, residents, and clinical and postdoctoral fellows whose abstracts were accepted for presentation, based on the quality of the abstracts. This year's awardees are:

SABCS Basic Science Scholar Award

- A novel cleaved cytoplasmic lncRNA LacRNA interacts with PHB2 and suppresses breast cancer metastasis via repressing MYC targets - **#P6-05-01: Rong Guo, MS**
- Acquired ESR1 mutation and persistent expression of estrogen regulated genes in ER+ breast cancers on long-term neoadjuvant treatment with aromatase inhibitors - **#P4-15-01: Mariana Ferreira Leal, PhD**
- A selective Cdk12/13 non-covalent inhibitor with potent anti-breast cancer activity - **#P1-06-03: Victor Quereda, PhD**
- Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion - **#P2-01-03: Emily S. Villodre, PhD**
- Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer - **#PD7-07: James Richard Whittle, MBBS**

SABCS Clinical Scholars Award

- A phase II study of copper-depletion using tetrathiomolybdate (TM) in patients (pts) with high risk breast cancer (BC): Role of collagen processing and tumor microenvironment - **#PD9-07: Ying Liu, MD, MPH**
- 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET imaging in staging extent of disease in metastatic lobular breast cancer - **#PD4-09: Poorni Manohar, MD**
- Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial - **#PD5-05: Bruno Valentin Sinn, Dr. Med.**
- Role of breast MRI in predicting pathologically negative nodes after neoadjuvant chemotherapy in cNO patients in the I-SPY2 trial - **#PD4-04: Marieke van der Noordaa, MD**
- Genetic testing and bilateral mastectomy for women with breast cancer: Does testing matter more than the test result? - **#P2-14-04: Francys Verdial, MD, MPH**

AACR Associate Member Award

- High APOBEC3C-H gene expression in tumor associates with better survival in breast cancer - **#P3-08-05: Mariko Asaoka, MD**
- Clonal evolution and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy - **#P3-06-01: Jennifer L. Caswell-Jin, MD**
- Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells - **#PD7-12: Cristina Guarducci, PhD**
- Neoadjuvant trial with letrozole identifies PRR11 in 17q21-23 amplicon as a resistance mechanism to endocrine therapy in ER-positive breast cancer - **#PD7-10: Kyung-min Lee, PhD**
- Regulation of BRCA1 by SIRT2 - **#P1-06-01: Elizabeth Virginia Minten, PhD**
- Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS) - **#P3-07-01: Sahil Seth, MS**
- Circulating CAF/cancer stem cell co-clusters bolster breast cancer metastasis: - **#PD9-11: Utsav Sharma, MS Biology**
- Immune parameters associated with survival in triple negative and HER2-positive breast cancer patients with 10 years of follow-up - **#PD5-09: Cinzia Solinas, MD**
- Novel human cell line xenograft models of ER α -positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers - **#PD7-02: Nilgun Tasdemir, PhD**
- Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer - **#P2-06-02: Suryavathi Viswanadhapalli, PhD**



PRODUCT THEATRE SCHEDULE

DECEMBER 5, 2018

11:00 AM

Treatment Considerations in Third-Line Metastatic Breast Cancer. *Presented by Eisai*

12:30 pm

A Case-Based Discussion of HER2+ Early Breast Cancer Treatment and the APHINITY Trial. *Presented by Genentech*

2:00 pm

Prosigna® Breast Cancer Prognostic Gene Signature Assay: Evidence & Implications from Recent Clinical Trials and Population Studies. *Presented by NanoString Technologies*

3:30 pm

Review of the Expanding Body of First-line, Phase III Evidence for a CDK4/6 Inhibitor for the Treatment of Women with HR+/HER2- mBC. *Presented by Novartis*

DECEMBER 6, 2018

11:00 AM

A Treatment Option for Patients with HR+, HER2- Advanced or Metastatic Breast Cancer
© Lilly USA, LLC 2018. All rights reserved.
Presented by Lilly

12:30 pm

How has the TAILORx Data Changed Clinical Practice? *Presented by Genomic Health*

2:00 pm

Make a First-in-Class Oral Therapy Your Partner of Choice for the Treatment of Women with HER+/HER2- Metastatic Breast Cancer. *Presented by Pfizer Oncology*

DECEMBER 7, 2018

11:00 AM

An Optimal Targeted Treatment for gBRCAm HER2- Metastatic Breast Cancer. *Presented by AstraZeneca*

12:30 pm

An Oral Treatment for gBRCA-mutated, HER2- Metastatic Breast Cancer. *Presented by Pfizer*

2:00 pm

Clonal ctDNA Monitoring with Signatera (RUO): Research Applications in Breast Cancer. *Presented by Natera*

3:30 pm

Are you Ready for Biosimilars? What the Oncologist Should Know. *Presented by Amgen*

*AT PRESS TIME

AWARDS

WILLIAM L. MCGUIRE MEMORIAL LECTURE

Wednesday, December 5, 11:15 AM, Hall 3

Hold That Scalpel! Using the Tumor to Determine the Treatment

Ian E. Smith, MD, FRCP, FRCPE

The Royal Marsden NHS Foundation Trust
London, UNITED KINGDOM

Smith, a professor of cancer medicine at The Royal Marsden and the Institute of Cancer Research in London, is being recognized for a lifetime of contributions that changed the direction of oncology in the United Kingdom and beyond. They include his research and testing of aromatase inhibitors, his pioneering of neoadjuvant (preoperative) endocrine therapy for patients with large, operable cancers, and major contributions to oncology training in the UK.

"The depth and breadth of his career have been stellar," said Norman Wolmark, MD, chairman and principal investigator of the National Surgical Adjuvant Breast and Bowel Project Foundation and the 2013 McGuire Award Lecturer. "There isn't one thing that proves seminal. It's his lifetime contributions to the field that are formidable."

Smith was involved in the early clinical development of several anticancer drugs that have subsequently proved effective in the clinic, including carboplatin and letrozole. In the last decade he has become increasingly involved in neoadjuvant therapies as a research approach towards individualized treatments for breast cancer.

"This is one of the most prestigious awards in the area of breast cancer," said Kent Osborne, MD, director of the SABCS Co-Sponsor, Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine in Houston. "This year's winner and all the nominees are the premier researchers." Smith said he was "thrilled" to learn he was the 2018 McGuire Lecture Award recipient, but also "overawed."

"I thought of the many recipients who have led and indeed defined breast cancer research throughout my career and I genuinely wondered if I had done enough to justify such a wonderful honor," Smith said. "I have been lucky enough to be involved in important areas of clinical research that have changed practice, and one of the great pleasures of this work has been its collaborative nature."

Smith is the chief investigator of the UK POETIC Trial, the largest of its kind. He was appointed first chairman of the UK Breast Trials Intergroup and chairman of the British Breast Group. Smith was the Scientific Chairman of the Breast Section of 2012 ESMO, and he has also chaired several national professional bodies including the Association of Cancer Physicians and the Royal College of Physicians Specialist Advisory Committee for Medical Oncology.

"Ian Smith has made a cumulative longitudinal contribution of moving the state of the art forward," said Wolmark, who is a member of the McGuire Award Selection Committee. "That's not easily done. In this day and age when we're all recognized for a soundbite, he's recognized for his consistency."

AWARDS

Funding for this conference was made possible (in part) by 5R13CA213939-03 SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES

Wednesday, December 5 2:15 PM – Hall 3

Established by Komen in 1992, the prestigious Brinker Awards for Scientific Distinction recognize advances in both our understanding of the underlying mechanisms of breast cancer (Basic Science) and the clinical setting (Clinical Research), which are both essential to combating the disease.

Modeling Immune Response: Lessons Learned from Mouse Models of Cancer Development

Dr. Coussens has made several pivotal discoveries about the role of immune cells in cancer development and progression. In a seminal study, she demonstrated that certain immune cells were actually “hijacked” by early tumors to promote breast cancer growth and metastasis. She and her team discovered an intricate cell-cell communication process through which tumor cells trigger T-lymphocytes or T-cells (a type of white blood cell involved in controlling the immune response to foreign substances) to recruit another type of white blood cell called macrophages to early tumors. Normally involved in clearing debris, macrophages around tumor cells produce epidermal growth factor (EGF) that in turn promotes tumor cell proliferation and invasion. This provocative finding expanded our understanding of the tumor microenvironment and sparked additional research aimed at reprogramming these immune cells by designing and then testing targeted and immune-based therapies to prevent them from aiding and abetting the cancer.

“We are excited to honor Dr. Coussens with this distinction. Her work is helping lay the foundation for the development and clinical use of immunotherapies that will significantly impact the future of breast cancer research and treatment,” said Komen’s Chief Scientific Advisor, Jennifer Pietenpol, Ph.D., Executive Vice President for Research at Vanderbilt University Medical Center, Director of the Vanderbilt-Ingram Cancer Center, the B.F. Byrd Jr. Professor of Molecular Oncology, and Professor of Biochemistry and Otolaryngology at Vanderbilt University School of Medicine. “In addition to her groundbreaking research, she is also an incredible mentor to countless young researchers helping to ensure that the next generation of scientists enter the breast cancer field.”

The Challenge of Doing Less

This year’s Brinker Award for Clinical Distinction in Clinical Research will be presented to Eric Winer, M.D., Professor of Medicine, Harvard Medical School, Senior Vice President for Medical Affairs, Director, Breast Cancer Program; Thompson Chair in Breast Cancer Research, Dana-Farber Cancer Institute in Boston, MA.

Dr. Winer is being honored for his devotion to applying the advances from clinical trials to daily practice to improve breast cancer patient care and quality of life. He has designed and conducted a wide array of clinical trials that have changed clinical practice or paved the way towards more personalized treatment of breast cancer. His career has focused on optimizing the treatment of breast cancer for specific patient populations. His clinical research has included multimodality studies to determine optimal drug doses and treatment durations, the best treatment sequence and the most effective drug combinations to treat early, locally advanced and metastatic breast cancers.

“Dr. Winer’s accomplishments in breast cancer research and in the clinic have impacted treatment for all stages and all the major biologic subtypes of the disease and led to lasting impact on patient outcomes,” said Komen’s Chief Scientific Advisor, Dr. George Sledge, M.D., Professor of Medicine, and Chief of the Division of Oncology in the Department of Medicine at Stanford University. “Throughout his career he has appreciated the impact treatment has on patients and has focused on developing greater individualization in treatment, so that we can achieve highly effective treatment with fewer side effects.”



SPECIAL APPRECIATION

CONFERENCE & EDUCATIONAL GRANTS

SABCS gratefully acknowledges Breast Cancer Research Foundation for generous support of the 2018 AACR Outstanding Investigator Award in Breast Cancer Research.

GRANTS

CONFERENCE GRANT

Funding for this conference was made possible (in part) by 5R13CA213939-03 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the US Government.

EDUCATIONAL GRANT

SABCS is supported in part by educational grants from industry.

This activity is supported by educational grants provided by AbbVie, Amgen, AstraZeneca, Eisai, Lilly USA, LLC (For further information concerning Lilly grant funding visit www.lillygrantoffice.com), Merck and Co, Inc., Novartis, Pfizer, and Tesaro.

SUPPORTERS

We are proud to acknowledge the following for their contributions to and generous support of our program.

PREMIER

AstraZeneca
Lilly

Novartis Oncology
Pfizer

ANGEL

Eisai Corporation
Genentech

Genomic Health
Merck and Co., Inc.

PATRON

Amgen
GlaxoSmithKline

Immunomedics

MAJOR SUPPORTER

Abbvie/Pharmacylics
Bristol-Myers Squibb
Myriad Genetic Laboratories, Inc.

NanoString Technologies
Puma Biotechnology, Inc.
TESARO

CONTRIBUTOR

Biotheranostics
Celgene Corporation
Daiichi Sankyo Inc.
H3 Biomedicine
Lumicell
MacroGenics, Inc.
Menarini Silicon Biosystems

Natera
Odonate Therapeutics Inc.
Seattle Genetics
Spectrum Pharmaceuticals
Syndax Pharmaceuticals, inc.
Wolters Kluwer

DONOR

23andMe
Agendia, inc.
Ambry Genetics
Caris Life Sciences
Cepheid
Cianna Medical
Coherus BioSciences
Dignitana
Elsevier, Inc.
Epic Sciences
Faxitron
Helsinn Therapeutics US, Inc.
K2 Oncology Co Ltd
Mitra Biotech

NeoGenomics Laboratories
The Oncologist
Paxman USA Inc.
Philips Molecular Pathway DX
PreludeDx
Radius Health, Inc.
RareCyte, Inc.
R-Pharma US
Springer Healthcare Education
Tempus
TerSera Therapeutics
Toray International America, Inc.
XEOS
Zero Gravity Skin

EXHIBITORS*

Visit the Exhibitors section of the SABCS Mobile App for more information from these companies.

23andMe	Faxitron	Paxman USA Inc.
Agendia, Inc.	Genentech	Pfizer
Alamo Breast Cancer Foundation	Genomic Health	Pfizer Biosimilars
Ambry Genetics	Global Breast Cancer Conference	Philips Molecular Pathway Dx
American Association for Cancer Research (AACR)	H3 Biomedicine	Physicians' Education Resource
Amgen	Harborside	Prelude Dx
Association of Community Cancer Centers	Helsinn Therapeutics	Puma Biotechnology, Inc.
AstraZeneca	The IBC Network Foundation	Radius Health Inc.
Baylor College of Medicine	Immunomedics, Inc.	RareCyte, Inc.
Best of SABCS / Encore Medical Education	JAMA Network	Roche Diagnostics
Biocept Inc.	Jeunesse Innovations	R-Pharm US
Biotheranostics	K2 Oncology Co Ltd.	Seattle Genetics
BRAVE Coalition Foundation	Lilly	Silbiotech, Inc.
Breast Cancer Action	Lumicell, Inc.	Spectrum Pharmaceuticals
Caris Life Sciences	MacroGenics, Inc.	Springer Healthcare Education
CDC Foundation	Male Breast Cancer Coalition	Susan G. Komen
Celgene Corporation	Medtronic	Syndax Pharmaceuticals, Inc.
Cepheid	Menarini Silicon Biosystems	Tempus
Cianna Medical	Merck & Co., Inc.	TerSera Therapeutics
Coherus BioSciences	Metastatic Breast Cancer Alliance	TESARO
Daiichi Sankyo Inc.	METavivor	Toray International America, Inc.
Dignitana	Mitra Biotech	TRIO - Translational Research In Oncology
Dove Medical Press Ltd	Myriad Genetic Laboratories, Inc.	UT MD Anderson Cancer Center
Eisai Corporation	NanoString Technologies	Wolters Kluwer
Elements/Furthermore Art Gallery	Natera	XEOS
Elsevier	NeoGenomics Laboratories	Zero Gravity Skin
Epic Sciences	Novartis Oncology	
	Odonate Therapeutics Inc.	
	The Oncologist	

Download the SAN ANTONIO BREAST CANCER SYMPOSIUM MOBILE APP



Navigate the event like a pro with the SABCS 2018 mobile app, powered by core-apps.com

WITH THE SABCS 2018 MOBILE APP, YOU CAN:

- Stay organized with up-to-the-minute Exhibitor, Speaker, and Event information
- Sync the app across all of your devices with Multi-Device Sync
- Receive important real-time communications from SABCS
- Build a personalized schedule and bookmark exhibitors
- Take notes and download event handouts and presentations
- Rate the sessions you attend and comment on them, too
- Interactively locate sessions and exhibitors on the Henry B. Gonzalez Convention Center maps
- Visit your bookmarked exhibitors with the Quick List
- Find attendees and connect with your Colleagues through Friends
- Stay in-the-know and join in on social media with #SABCS
- And much, much more!

DOWNLOADING THE APP IS EASY!

SEARCH:

The App Store or Google Play for "SABCS"



SCAN:



Once you have downloaded and opened the app, choose SABCS 2018 and tap Download.

If you already have the SABCS app on your device, tap "Exit to show list" under Settings. Choose SABCS 2018 then tap download.

Also available at:

www.core-apps.com/dl/sabcs2018

Questions:

support@core-apps.com

Platform Compatibility:

Android v4x+ and iOS v7x+